Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12Cand STK11 mutations: KRYSTAL-1 phase 2 cohort
Year: 2025
Type: conference-abstract
Source: Cancer Research
Institutions: The University of Texas MD Anderson Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Roswell Park Comprehensive Cancer Center, Virginia Cancer Specialists, Sarah Cannon, Henry Ford Health, Dana-Farber Cancer Institute, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Cincinnati Medical Center, University of Colorado Anschutz, Medical Oncology Hematology Consultants, Bristol-Myers Squibb (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409821999